Incannex Completes Dosing in Phase 1 Clinical Trial to Assess Multi-Use, Anti-Inflammatory Drug IHL-675A; Proceeds to Phase 2 Clinical Trials Highlights: Patient dosing has been completed in the Phase 1 clinical trial measuring the safety, tolerability, and pharmacokinetic profiles of IHL-675AIHL-675A has been well tolerated, with no...

Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-216A for Treatment of Concussion and Traumatic Brain Injury MELBOURNE, Australia, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or the ‘Company’), a clinical-stage pharmaceutical company developing unique...

Incannex to Participate in the Prestigious H.C. Wainwright 24th Annual Global Investment Conference MELBOURNE, Australia, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a pharmaceutical company developing medicinal...

Incannex Appoints FDA Regulatory Affairs Expert Mr Robert B. Clark to the Board of Directors Highlights: Highly experienced pharmaceutical executive with 20+ years at Pfizer and 10+ years at Novo NordiskSecured FDA registration and marketing approval for 12 significant new drugs in the past...